Initial Analysis of Lipid Metabolomic Profile Reveals Differential Expression Features in Myeloid Malignancies

Abstract

Introduction: Lipids are molecules that stand out among the different cellular metabolites by their enormous molecular diversity. Their functions were initially related to the composition of biological membranes and energy storage, but currently, these molecules have been analyzed considering different functions and regulatory signaling (Loizides-Mangold, 2013). It is known that lipid membranes and lipid mediators constitute specific phenotypes, including tumors (Hilvo et al, 2011). Lipid metabolism in cancer had been studied predominantly at the genetic level has recently gained further interest. Lipidomics studies show a powerful means of investigating pathophysiological issues and involvement of lipids in pathological states for both diseases in which lipids are known to play a role, but also for those which role is not well characterized (Roberts et al., 2008). Myeloid neoplasms are clonal diseases of the hematopoietic stem cell which can be present in the bone marrow and/or peripheral blood. Over the past two decades, mass spectrometry (MS) has emerged as the main method used in lipidomics analysis, which allows the structural characterization and quantification of complex lipids and their metabolites (MURPHY et al, 2005). Due to the importance of this field we have considered the use of the lipidomic innovative platform to identify differences in the plasma lipid metabolomic profile of hematological patients with Myeloid Neoplasms. Methods: Untargeted Shotgun MS/MS Analysis was performed on an independent service at the AB-Sciex Laboratory located in Sao Paulo, SP, Brazil on a 5600 Triple TOF mass spectrometer (ABSciex) instrument with an acquisition scan rate of 100 spectra/sec and stable mass accuracy of ~2 ppm. Plasma samples from 153 participants were analyzed being, 90 of the Control Group, 43 Myeloproliferative Neoplasms (MPN), 11 Myelodysplastic Syndromes (MDS) and 9 Acute Myeloid Leukemias (AML). Data were acquired using the AB-Sciex Analyst TF, processed using the AB-Sciex LipidViewTM and the web-based analytical pipeline MetaboAnalyst 2.0 (www.metaboanalyst.ca) (Xia et al, 2012). Results: Untargeted analysis identified in negative and positive-modes a total of 658 features at 2 ppm resolution. PCA and PLS-DA analysis revealed clear discrimination among groups, in particular for AML patients. Main lipid groups differentially expressed were: Monoacylglycerols (MAG), Glucosylceramide E (GlcdE), Ethyl Esters (EE), Lysophosphatidic acid (LPA), Sulfoquinovosil diacylglycerols (SQDG), Monoglycerols (MG), Methyl Ethanolamines (ME), Lysophosphatidylcholines (LPC), Dimethyl Phosfatidyletanilamines (DMPE), Monometylphosphatidiletanolamines (MMPE), Ceramide-1-phosphate (CerP), Glicerophosphoglycerols (GP), Lysomonomethyl Glycerophosphocholine (LMMPE), Phosphatidic Acids (PA), Ergosterols (ERG), Glycerophosphoserine (PS), Diacylglycerols (DAG), Hexocylceramides (HexCer) and Lanosterol (Lan). ROC Curve Analysis revealed Total LMMPE as the strongest discriminating marker between Controls from Patients with MDS or AML (Sensitivity= 0.95 (0.824-1); Specificity= 0.8941 (0.847-0953); Positive Likelihood Ratio= 8.972 and Negative Likelihood Ratio =0.05592 and T Test= 7.576E-12). In addition these lipids were also able to differentiate MDS and AML from NMP (Sensitivity= 0.9118 (0.824-1), Specificity= 0.95 (0.85-1), Positive Likelihood Ratio= 18.2 and Negative Likelihood Ratio= 0.05592). Conclusions: The Myeloproliferative Neoplasms from the point of view of global plasma lipidomics are accompanied by several modifications. In particular the Lysomonomethyl-Phosphatidylethanolamines (LMMPE) seems to play important differentiating roles among them. Disclosures No relevant conflicts of interest to declare.

Plasma Lipidome Acts As Diagnostic Marker and Predictor for Cyclosporin Response in Patients with Aplastic Anemia

“…With the development of mass spectrometry, the lipidomic analysis of peripheral blood was used to investigate the role of lipid on the pathophysiology of hematological diseases. In 2014, Adriana et al reported discriminative lipid pro les in patients with AML, MDS, and myeloproliferative neoplasms using untargeted shotgun LC-MS/MS analyses (3). Although studies on AML and MDS have illustrated the inner correlations of the two entities to some extent, very few studies have focused on the lipid pro les of patients with AA, let alone the comparison of the changes after CsA treatment and the difference between AA and h-MDS.…”

“…It had been used in the early diagnosis, progression and treatment for cancer and other diseases. With regard to hematological diseases, the lipid metabolomic pro le was found to be different in the different myeloid diseases (3). Studies found that the serum sphingomyelin species containing saturated odd chain fatty acids (OCFAs) in the side chain were lower in leukemia and MDS patients compared to normal serum.…”

Revealing serum lipidomic characteristics and potential lipid biomarkers in patients with POEMS syndrome

“…A serum lipidomic study on patients with acute myeloid leukaemia and myelodysplastic syndromes showed that the levels of lysomonomethyl glycerophosphocholine could effectively distinguish these patients from healthy controls. 4 A study of the serum lipidome in patients with multiple myeloma demonstrated that serum arachidonic acid levels diminished significantly in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) compared with healthy controls. Supplementation with arachidonic acid by injection in MM mice could induce ferroptosis of MM cells, indicating a new drug target for MM.…”

Sample Preparation in Centrifugal Microfluidic Discs for Human Serum Metabolite Analysis by Surface Assisted Laser Desorption/Ionization Mass Spectrometry

“…Metabolomic studies can facilitate biomarker discovery, − diagnosis of disease, − and toxic effect assessment of drugs, toxins, and food additives. − Considerable interest is focused on small-molecule metabolites (<1500 Da) such as amino acids, ,, lipids, − and fatty acids. , Once useful health markers are known, batch-processed, spot analyses are an attractive approach to routine assays. Analyzing blood-derived samples, such as serum, is of primary interest for metabolite assays, but a high concentration of proteins, as well as other biomolecules, usually generates interferences in the following detection step, so sample preparation is required.…”